With the aim at improving the anticancer effects of gene therapy against LC cells, Pan et al. synthetized an FTIC-labelled CNT-based nanocomposite, conjugating the antisense c-myc oligonucleotides (asODN) and poly-ethyleneimine (PAMAM-NH2) of different generations to MWCNTs, achieving as-ODNs@PAMAM@f-MWCNTs composites which were administered to liver cancer cell line HepG2 cells [136]. The gene discussed is MYC; the disease is laryngotracheoesophageal cleft.